| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/03/2003 | WO2002002603A3 Protein modification and maintenance molecules |
| 01/03/2003 | WO2002002563A3 Substituted-triazolopyrimidines as anticancer agents |
| 01/03/2003 | WO2002000727A3 Gp286 nucleic acids and polypeptides |
| 01/03/2003 | WO2001098468A3 Proteases |
| 01/03/2003 | WO2001098357A3 Compositions and methods of monoclonal and polyclonal antibodies specific for t cell subpopulations |
| 01/03/2003 | WO2001092528A3 Method of diagnosing, monitoring, staging, imaging and treating colon cancer |
| 01/03/2003 | WO2001081551A8 Retinal pigment epithelial cell lines with extended life-span and their applications |
| 01/03/2003 | WO2001044260A8 Novel purines |
| 01/03/2003 | CA2633595A1 Antibodies against tumor-associated antigenic target (tat) polypeptides |
| 01/03/2003 | CA2489420A1 Oncology drug innovation |
| 01/03/2003 | CA2459985A1 Pancam nucleic acids and polypeptides |
| 01/03/2003 | CA2454538A1 Quinoline derivatives and quinazoline derivatives capable of inhibiting autophosphorylation of hepatocyte growth factor receptors, and pharmaceutical composition comprising the same |
| 01/03/2003 | CA2452088A1 Compositions and methods for intracellular delivery |
| 01/03/2003 | CA2452049A1 Uses of dc-sign and dc-signr for inhibiting hepatitis c virus infection |
| 01/03/2003 | CA2451841A1 Method for enhancing the effectiveness of cancer therapies |
| 01/03/2003 | CA2451745A1 .beta.-2'-or 3'-halonucleosides |
| 01/03/2003 | CA2451637A1 Liver engrafting cells, assays, and uses thereof |
| 01/03/2003 | CA2451625A1 Substituted n-acyl-aniline derivatives, the preparation thereof and the use thereof as pharmaceutical compositions |
| 01/03/2003 | CA2451493A1 Cell growth inhibitors containing anti-glypican 3 antibody |
| 01/03/2003 | CA2451351A1 A method for diagnosing a person having multiple sclerosis |
| 01/03/2003 | CA2451271A1 Pancam nucleic acids and polypeptides |
| 01/03/2003 | CA2451239A1 Antibodies against tumor-associated antigenic taget (tat) polypeptides |
| 01/03/2003 | CA2451185A1 Spherical protein particles and methods of making and using them |
| 01/03/2003 | CA2451138A1 Remedies for eosinophilic diseases |
| 01/03/2003 | CA2450969A1 Nucleic acid-associated proteins |
| 01/03/2003 | CA2450942A1 Method of treating hyperproliferative diseases using active vitamin d analogues |
| 01/03/2003 | CA2450921A1 Protein modification and maintenance molecules |
| 01/03/2003 | CA2450828A1 Humanized antibodies derived from dd-3b6/22, specific for the d-dimer fragment of fibrin |
| 01/03/2003 | CA2450579A1 Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 01/03/2003 | CA2450562A1 Tyrosine kinase inhibitors |
| 01/03/2003 | CA2450478A1 Complex mixtures exhibiting selective inhibition of cyclooxygenase-2 |
| 01/03/2003 | CA2450475A1 Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 01/03/2003 | CA2450446A1 Pharmaceutical compositions which inhibit proliferation of pituitary adenomas and method of use thereof |
| 01/03/2003 | CA2449844A1 Naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
| 01/03/2003 | CA2446205A1 Water-soluble antibiotic comprising an amino sugar, in the form of a polysaccharide conjugate |
| 01/02/2003 | US20030005470 Animal model for use in the diagnosis and treatment of tumors and bone matastasis |
| 01/02/2003 | US20030004499 Method and apparatus for the photomodulation of living cells |
| 01/02/2003 | US20030004351 Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors |
| 01/02/2003 | US20030004350 Pyrrolo(2,3-b)pyridine derivatives; anticancer and antiproliferative agents |
| 01/02/2003 | US20030004334 Water-soluble porphyrin derivatives and methods of their preparation |
| 01/02/2003 | US20030004324 31 human secreted proteins |
| 01/02/2003 | US20030004317 Nucleic acids encoding anti-human alphanubeta3 and alphanubeta5 antibodies |
| 01/02/2003 | US20030004310 Culture product |
| 01/02/2003 | US20030004210 Coupling to cell binding agent; killing cells |
| 01/02/2003 | US20030004193 Immunomodulators; antiinflammatory agents |
| 01/02/2003 | US20030004191 Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor |
| 01/02/2003 | US20030004174 Antiinflammatory agents, anticancer agents, antihistamines, central nervous system disorders |
| 01/02/2003 | US20030004172 Cardiovascular disorders, osteoporosis, multiple sclerosis, antiarthritic agents |
| 01/02/2003 | US20030004165 Polyazanaphthalene compounds and pharmaceutical use thereof |
| 01/02/2003 | US20030004164 Anticancer agents; autoimmune diseases |
| 01/02/2003 | US20030004161 Anticancer agents; autoimmune diseases |
| 01/02/2003 | US20030004156 Anticholesterol agents; cardiovascular disorders; antidiabetic agents; antiproliferative agents |
| 01/02/2003 | US20030004146 Compositions for preventing hormone induced adverse effects |
| 01/02/2003 | US20030004144 Anticancer agents; skin disorders |
| 01/02/2003 | US20030004143 In situ supplying; anticancer, antitumor agents |
| 01/02/2003 | US20030004142 In situ supplying; anticancer, antitumor agents |
| 01/02/2003 | US20030004137 Muscle relaxants, controlling immunology, strokes, antidiabetic agents |
| 01/02/2003 | US20030004136 IL-8 receptor ligands-drugs for inflammatory and autoimmune diseases |
| 01/02/2003 | US20030004129 Formulations of adenosine a1 agonists |
| 01/02/2003 | US20030004117 Methods for inhibiting angiogenesis |
| 01/02/2003 | US20030004093 Method for identifying compounds for inhibition of neoplastic lesions |
| 01/02/2003 | US20030003555 Nucleotide sequences coding proteins for use in the diagnosis and treatment of hematopoietic or immune disorders |
| 01/02/2003 | US20030003545 Nucleotide sequences coding polypeptide for use in the treatment of immunological defects |
| 01/02/2003 | US20030003541 Nucleotide sequences coding peptide for use in the treatment of skin, brain and eye disorders |
| 01/02/2003 | US20030003532 Novel nucleic acid sequences encoding human slit-, megf-, and roundabout-like polypeptides |
| 01/02/2003 | US20030003511 Closure of bacterial ghost |
| 01/02/2003 | US20030003462 Novel human interleukin-like proteins and polynucleotides encoding them |
| 01/02/2003 | US20030003453 DNA molecule encoding a variant paraoxonase and uses thereof |
| 01/02/2003 | US20030003169 Prepared by fermenting an aqueous Glycine max (L.) extract with at least one lactic acid bacteria together with at least one yeast |
| 01/02/2003 | US20030003159 Anticancer agents comprising powders of head and neck of soft-shelled turtle, bear gall, achyranthes root, bitter almond, black ant, rhubarb and muskiness |
| 01/02/2003 | US20030003150 System for osmotic delivery of pharmaceutically active agents |
| 01/02/2003 | US20030003120 A phenolic fraction of fruit obtained from the Rosaceae family, including at least 10% by weight of the sum of phloridzin, chlorogenic acid, epicatechin, quercitrin, procyanidin B2, p-coumaric acid and caffeic acid |
| 01/02/2003 | US20030003114 Hexosaminidase covalently attached to a cancer cell targeting ligand; improves selectively of the hexosaminidase for tumor cells |
| 01/02/2003 | US20030003106 Use of protein derived from cancer cells, cells infected by a virus or immune cells or an inactive fragment thereof, protein being initially an immunosuppressive and/or angiogenic protein for obtaining medicines to provide mucosal immunity |
| 01/02/2003 | US20030003102 Morpholino imaging and therapy |
| 01/02/2003 | US20030003101 Treatment and diagnosis of prostate cancer |
| 01/02/2003 | US20030003097 Recombinant antibodies coexpressed with GnTIII |
| 01/02/2003 | US20030003094 Compound which disrupts microtubule function and polymeric carrier, with proviso that polymeric carrier is not a capsule |
| 01/02/2003 | US20030003092 Administering an immunotherapeautic agent in conjunction with a tumour growth restricting agent, in amounts effective to eradicate any advanced or large tumours present |
| 01/02/2003 | US20030003085 Drug delivery of a muscle protein by administering purified donor muscle side population cells; gene therapy, in the treatment muscle diseases muscular dystrophies, genetic diseases, treating cancer, and bone marrow transplant |
| 01/02/2003 | US20030003080 Reovirus for the treatment of cellular proliferative disorders |
| 01/02/2003 | US20030003079 Recombinant pox virus for immunization against tumor-associated antigens |
| 01/02/2003 | US20030003076 Adenovirus E1B-55K single amino acid mutants and methods of use |
| 01/02/2003 | US20030003074 Comprising a biodegradable block copolymeric drug carrier having thermally reversible gelation properties; sustained release of an interleukin-2, no side effects |
| 01/02/2003 | US20030003047 Tumor radiotherapy |
| 01/02/2003 | EP1271153A2 Collapsin response mediator protein-1 as tumor metastasis marker |
| 01/02/2003 | EP1271146A1 Method and composition of cellular reprogramming |
| 01/02/2003 | EP1270732A1 Improved transfection of eukaryontic cells with linear polynucleotides by electroporation |
| 01/02/2003 | EP1270579A1 Process for producing camptothecin |
| 01/02/2003 | EP1270570A1 Amide compounds and use thereof |
| 01/02/2003 | EP1270559A1 Novel imidazole derivatives with anti-inflammatory activity |
| 01/02/2003 | EP1270017A1 Drugs for the diagnosis of tissue-reproductive activity or the treatment of proliferative diseases |
| 01/02/2003 | EP1270015A2 A complex comprising OCIF and Polysaccharide |
| 01/02/2003 | EP1270008A2 Fused tricyclic analogues of guanosine for treating tumors |
| 01/02/2003 | EP1269196A1 Method of screening for inhibitors of osteopontin |
| 01/02/2003 | EP1269191A1 Docosahexaenoic acid as retinoid x receptor and uses thereof |
| 01/02/2003 | EP1269183A1 Assay for agents that induce chemokinesis |
| 01/02/2003 | EP1268861A2 Diagnosis of diseases associated with dna transcription |
| 01/02/2003 | EP1268857A2 Diagnosis of diseases associated with gene regulation |
| 01/02/2003 | EP1268855A2 Diagnosis of diseases associated with tumor suppressor genes and oncogenes |